IDEAYA Biosciences, Inc. (IDYA) Stock Competitors & Peer Comparison
See (IDYA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IDYA | $36.74 | +1.24% | 3.5B | -22.96 | -$1.60 | N/A |
| VRTX | $491.34 | +2.32% | 124.7B | 26.11 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $632.90 | +2.06% | 65.2B | 13.87 | $45.63 | +0.58% |
| ARGX | $887.18 | -0.17% | 54.9B | 80.07 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $8.85 | +5.73% | 39.7B | -2.13 | -$4.15 | N/A |
| ALNY | $291.37 | -0.61% | 38.9B | 52.55 | $5.55 | N/A |
| RVMD | $182.08 | +2.19% | 38.7B | -25.75 | -$7.07 | N/A |
| ONC | $279.89 | +1.65% | 29.9B | 62.62 | $4.47 | N/A |
Stock Comparison
IDYA vs VRTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, VRTX has a market cap of 124.7B. Regarding current trading prices, IDYA is priced at $36.74, while VRTX trades at $491.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas VRTX's P/E ratio is 26.11. In terms of profitability, IDYA's ROE is -0.14%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, IDYA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VRTX's competition here
IDYA vs VRNA Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IDYA is priced at $36.74, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IDYA's ROE is -0.14%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, IDYA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check VRNA's competition here
IDYA vs REGN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, REGN has a market cap of 65.2B. Regarding current trading prices, IDYA is priced at $36.74, while REGN trades at $632.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas REGN's P/E ratio is 13.87. In terms of profitability, IDYA's ROE is -0.14%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IDYA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check REGN's competition here
IDYA vs ARGX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ARGX has a market cap of 54.9B. Regarding current trading prices, IDYA is priced at $36.74, while ARGX trades at $887.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ARGX's P/E ratio is 80.07. In terms of profitability, IDYA's ROE is -0.14%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, IDYA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARGX's competition here
IDYA vs SGEN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IDYA is priced at $36.74, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IDYA's ROE is -0.14%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IDYA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SGEN's competition here
IDYA vs RVMDW Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RVMDW has a market cap of 39.7B. Regarding current trading prices, IDYA is priced at $36.74, while RVMDW trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RVMDW's P/E ratio is -2.13. In terms of profitability, IDYA's ROE is -0.14%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, IDYA is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RVMDW's competition here
IDYA vs ALNY Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ALNY has a market cap of 38.9B. Regarding current trading prices, IDYA is priced at $36.74, while ALNY trades at $291.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ALNY's P/E ratio is 52.55. In terms of profitability, IDYA's ROE is -0.14%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, IDYA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ALNY's competition here
IDYA vs RVMD Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RVMD has a market cap of 38.7B. Regarding current trading prices, IDYA is priced at $36.74, while RVMD trades at $182.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RVMD's P/E ratio is -25.75. In terms of profitability, IDYA's ROE is -0.14%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, IDYA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RVMD's competition here
IDYA vs ONC Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ONC has a market cap of 29.9B. Regarding current trading prices, IDYA is priced at $36.74, while ONC trades at $279.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ONC's P/E ratio is 62.62. In terms of profitability, IDYA's ROE is -0.14%, compared to ONC's ROE of +0.12%. Regarding short-term risk, IDYA is less volatile compared to ONC. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ONC's competition here
IDYA vs MRNA Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MRNA has a market cap of 26.7B. Regarding current trading prices, IDYA is priced at $36.74, while MRNA trades at $67.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MRNA's P/E ratio is -8.25. In terms of profitability, IDYA's ROE is -0.14%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, IDYA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MRNA's competition here
IDYA vs ROIV Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, IDYA is priced at $36.74, while ROIV trades at $34.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ROIV's P/E ratio is -37.81. In terms of profitability, IDYA's ROE is -0.14%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, IDYA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ROIV's competition here
IDYA vs BNTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, IDYA is priced at $36.74, while BNTX trades at $91.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BNTX's P/E ratio is -19.74. In terms of profitability, IDYA's ROE is -0.14%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, IDYA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BNTX's competition here
IDYA vs UTHR Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, IDYA is priced at $36.74, while UTHR trades at $542.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas UTHR's P/E ratio is 20.03. In terms of profitability, IDYA's ROE is -0.14%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IDYA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check UTHR's competition here
IDYA vs INCY Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, INCY has a market cap of 22.7B. Regarding current trading prices, IDYA is priced at $36.74, while INCY trades at $113.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas INCY's P/E ratio is 15.29. In terms of profitability, IDYA's ROE is -0.14%, compared to INCY's ROE of +0.29%. Regarding short-term risk, IDYA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check INCY's competition here
IDYA vs INSM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, INSM has a market cap of 22.4B. Regarding current trading prices, IDYA is priced at $36.74, while INSM trades at $103.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas INSM's P/E ratio is -17.98. In terms of profitability, IDYA's ROE is -0.14%, compared to INSM's ROE of -1.30%. Regarding short-term risk, IDYA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check INSM's competition here
IDYA vs BGNE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IDYA is priced at $36.74, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IDYA's ROE is -0.14%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, IDYA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BGNE's competition here
IDYA vs DNA-WT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IDYA is priced at $36.74, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.14%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, IDYA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNA-WT's competition here
IDYA vs NBIX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, IDYA is priced at $36.74, while NBIX trades at $168.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas NBIX's P/E ratio is 24.35. In terms of profitability, IDYA's ROE is -0.14%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, IDYA is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check NBIX's competition here
IDYA vs ASND Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, IDYA is priced at $36.74, while ASND trades at $260.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ASND's P/E ratio is -107.75. In terms of profitability, IDYA's ROE is -0.14%, compared to ASND's ROE of -56.42%. Regarding short-term risk, IDYA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ASND's competition here
IDYA vs GMAB Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, GMAB has a market cap of 16B. Regarding current trading prices, IDYA is priced at $36.74, while GMAB trades at $26.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas GMAB's P/E ratio is 18.79. In terms of profitability, IDYA's ROE is -0.14%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, IDYA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check GMAB's competition here
IDYA vs JAZZ Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, JAZZ has a market cap of 14.4B. Regarding current trading prices, IDYA is priced at $36.74, while JAZZ trades at $230.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas JAZZ's P/E ratio is 17.89. In terms of profitability, IDYA's ROE is -0.14%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, IDYA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check JAZZ's competition here
IDYA vs EXEL Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, EXEL has a market cap of 13.8B. Regarding current trading prices, IDYA is priced at $36.74, while EXEL trades at $54.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas EXEL's P/E ratio is 16.40. In terms of profitability, IDYA's ROE is -0.14%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, IDYA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check EXEL's competition here
IDYA vs BBIO Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BBIO has a market cap of 13.8B. Regarding current trading prices, IDYA is priced at $36.74, while BBIO trades at $70.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BBIO's P/E ratio is -18.78. In terms of profitability, IDYA's ROE is -0.14%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, IDYA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BBIO's competition here
IDYA vs IONS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, IONS has a market cap of 13.4B. Regarding current trading prices, IDYA is priced at $36.74, while IONS trades at $81.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas IONS's P/E ratio is -47.20. In terms of profitability, IDYA's ROE is -0.14%, compared to IONS's ROE of -0.59%. Regarding short-term risk, IDYA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IONS's competition here
IDYA vs KRTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IDYA is priced at $36.74, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IDYA's ROE is -0.14%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IDYA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check KRTX's competition here
IDYA vs AXSM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, IDYA is priced at $36.74, while AXSM trades at $241.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas AXSM's P/E ratio is -63.10. In terms of profitability, IDYA's ROE is -0.14%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, IDYA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check AXSM's competition here
IDYA vs MDGL Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, IDYA is priced at $36.74, while MDGL trades at $512.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MDGL's P/E ratio is -40.05. In terms of profitability, IDYA's ROE is -0.14%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, IDYA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MDGL's competition here
IDYA vs BMRN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, IDYA is priced at $36.74, while BMRN trades at $59.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BMRN's P/E ratio is 28.37. In terms of profitability, IDYA's ROE is -0.14%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, IDYA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BMRN's competition here
IDYA vs RNAM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IDYA is priced at $36.74, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IDYA's ROE is -0.14%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IDYA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RNAM's competition here
IDYA vs TECH Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, IDYA is priced at $36.74, while TECH trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas TECH's P/E ratio is 154.58. In terms of profitability, IDYA's ROE is -0.14%, compared to TECH's ROE of +0.05%. Regarding short-term risk, IDYA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TECH's competition here
IDYA vs ARWR Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, IDYA is priced at $36.74, while ARWR trades at $78.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ARWR's P/E ratio is -36.69. In terms of profitability, IDYA's ROE is -0.14%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, IDYA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ARWR's competition here
IDYA vs KRYS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, KRYS has a market cap of 11B. Regarding current trading prices, IDYA is priced at $36.74, while KRYS trades at $372.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas KRYS's P/E ratio is 49.77. In terms of profitability, IDYA's ROE is -0.14%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IDYA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KRYS's competition here
IDYA vs SMMT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, IDYA is priced at $36.74, while SMMT trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas SMMT's P/E ratio is -8.76. In terms of profitability, IDYA's ROE is -0.14%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, IDYA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check SMMT's competition here
IDYA vs CYTK Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, IDYA is priced at $36.74, while CYTK trades at $82.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CYTK's P/E ratio is -14.10. In terms of profitability, IDYA's ROE is -0.14%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, IDYA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CYTK's competition here
IDYA vs RXDX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IDYA is priced at $36.74, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IDYA's ROE is -0.14%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RXDX's competition here
IDYA vs CORT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CORT has a market cap of 9.4B. Regarding current trading prices, IDYA is priced at $36.74, while CORT trades at $87.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CORT's P/E ratio is 249.49. In terms of profitability, IDYA's ROE is -0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, IDYA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CORT's competition here
IDYA vs ALKS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ALKS has a market cap of 9.2B. Regarding current trading prices, IDYA is priced at $36.74, while ALKS trades at $55.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ALKS's P/E ratio is 57.98. In terms of profitability, IDYA's ROE is -0.14%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, IDYA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ALKS's competition here
IDYA vs IBRX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, IDYA is priced at $36.74, while IBRX trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas IBRX's P/E ratio is -27.22. In terms of profitability, IDYA's ROE is -0.14%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, IDYA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IBRX's competition here
IDYA vs NUVL Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IDYA is priced at $36.74, while NUVL trades at $123.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas NUVL's P/E ratio is -21.71. In terms of profitability, IDYA's ROE is -0.14%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IDYA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check NUVL's competition here
IDYA vs KYMR Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, KYMR has a market cap of 8.9B. Regarding current trading prices, IDYA is priced at $36.74, while KYMR trades at $108.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas KYMR's P/E ratio is -30.63. In terms of profitability, IDYA's ROE is -0.14%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, IDYA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check KYMR's competition here
IDYA vs HALO Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, HALO has a market cap of 8.9B. Regarding current trading prices, IDYA is priced at $36.74, while HALO trades at $74.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas HALO's P/E ratio is 16.23. In terms of profitability, IDYA's ROE is -0.14%, compared to HALO's ROE of +1.26%. Regarding short-term risk, IDYA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check HALO's competition here
IDYA vs IMGN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IDYA is priced at $36.74, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IDYA's ROE is -0.14%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IDYA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check IMGN's competition here
IDYA vs TGTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, IDYA is priced at $36.74, while TGTX trades at $55.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas TGTX's P/E ratio is 19.19. In terms of profitability, IDYA's ROE is -0.14%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, IDYA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TGTX's competition here
IDYA vs BPMC Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IDYA is priced at $36.74, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IDYA's ROE is -0.14%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, IDYA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check BPMC's competition here
IDYA vs CERE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $36.74, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CERE's P/E ratio is -16.47. In terms of profitability, IDYA's ROE is -0.14%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IDYA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CERE's competition here
IDYA vs APGE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $36.74, while APGE trades at $132.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas APGE's P/E ratio is -30.61. In terms of profitability, IDYA's ROE is -0.14%, compared to APGE's ROE of -0.33%. Regarding short-term risk, IDYA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check APGE's competition here
IDYA vs PCVX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, IDYA is priced at $36.74, while PCVX trades at $56.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas PCVX's P/E ratio is -8.22. In terms of profitability, IDYA's ROE is -0.14%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, IDYA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PCVX's competition here
IDYA vs IMVT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, IDYA is priced at $36.74, while IMVT trades at $38.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas IMVT's P/E ratio is -14.55. In terms of profitability, IDYA's ROE is -0.14%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, IDYA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check IMVT's competition here
IDYA vs PTGX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, PTGX has a market cap of 7.8B. Regarding current trading prices, IDYA is priced at $36.74, while PTGX trades at $121.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas PTGX's P/E ratio is -67.34. In terms of profitability, IDYA's ROE is -0.14%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, IDYA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PTGX's competition here
IDYA vs RYTM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, IDYA is priced at $36.74, while RYTM trades at $109.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RYTM's P/E ratio is -35.09. In terms of profitability, IDYA's ROE is -0.14%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, IDYA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check RYTM's competition here
IDYA vs MTSR Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IDYA is priced at $36.74, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IDYA's ROE is -0.14%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, IDYA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MTSR's competition here
IDYA vs PTCT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, PTCT has a market cap of 7B. Regarding current trading prices, IDYA is priced at $36.74, while PTCT trades at $84.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas PTCT's P/E ratio is -36.24. In terms of profitability, IDYA's ROE is -0.14%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, IDYA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PTCT's competition here
IDYA vs LQDA Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, LQDA has a market cap of 6.9B. Regarding current trading prices, IDYA is priced at $36.74, while LQDA trades at $78.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas LQDA's P/E ratio is 557.43. In terms of profitability, IDYA's ROE is -0.14%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, IDYA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check LQDA's competition here
IDYA vs PRAX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, IDYA is priced at $36.74, while PRAX trades at $327.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas PRAX's P/E ratio is -24.52. In terms of profitability, IDYA's ROE is -0.14%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, IDYA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check PRAX's competition here
IDYA vs MRUS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IDYA is priced at $36.74, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IDYA's ROE is -0.14%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, IDYA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRUS's competition here
IDYA vs ACLX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IDYA is priced at $36.74, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IDYA's ROE is -0.14%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IDYA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ACLX's competition here
IDYA vs RETA Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $36.74, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RETA's P/E ratio is -66.29. In terms of profitability, IDYA's ROE is -0.14%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IDYA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RETA's competition here
IDYA vs SRRK Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, IDYA is priced at $36.74, while SRRK trades at $54.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas SRRK's P/E ratio is -15.25. In terms of profitability, IDYA's ROE is -0.14%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, IDYA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check SRRK's competition here
IDYA vs COGT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, IDYA is priced at $36.74, while COGT trades at $38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas COGT's P/E ratio is -18.06. In terms of profitability, IDYA's ROE is -0.14%, compared to COGT's ROE of -0.83%. Regarding short-term risk, IDYA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check COGT's competition here
IDYA vs ABVX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, IDYA is priced at $36.74, while ABVX trades at $97.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ABVX's P/E ratio is -51.00. In terms of profitability, IDYA's ROE is -0.14%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, IDYA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ABVX's competition here
IDYA vs CGON Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, IDYA is priced at $36.74, while CGON trades at $71.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CGON's P/E ratio is -30.88. In terms of profitability, IDYA's ROE is -0.14%, compared to CGON's ROE of -0.23%. Regarding short-term risk, IDYA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CGON's competition here
IDYA vs CNTA Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IDYA is priced at $36.74, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IDYA's ROE is -0.14%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IDYA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CNTA's competition here
IDYA vs MIRM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, IDYA is priced at $36.74, while MIRM trades at $123.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MIRM's P/E ratio is -9.09. In terms of profitability, IDYA's ROE is -0.14%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, IDYA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MIRM's competition here
IDYA vs LGND Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, IDYA is priced at $36.74, while LGND trades at $303.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas LGND's P/E ratio is 36.40. In terms of profitability, IDYA's ROE is -0.14%, compared to LGND's ROE of +0.16%. Regarding short-term risk, IDYA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check LGND's competition here
IDYA vs BLTE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, IDYA is priced at $36.74, while BLTE trades at $148.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BLTE's P/E ratio is -79.53. In terms of profitability, IDYA's ROE is -0.14%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, IDYA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BLTE's competition here
IDYA vs CDTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IDYA is priced at $36.74, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IDYA's ROE is -0.14%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, IDYA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CDTX's competition here
IDYA vs ABCM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $36.74, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IDYA's ROE is -0.14%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IDYA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ABCM's competition here
IDYA vs ISEE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $36.74, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IDYA's ROE is -0.14%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IDYA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ISEE's competition here
IDYA vs TVTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, IDYA is priced at $36.74, while TVTX trades at $58.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas TVTX's P/E ratio is -267.50. In terms of profitability, IDYA's ROE is -0.14%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, IDYA is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TVTX's competition here
IDYA vs SYRE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, SYRE has a market cap of 5.3B. Regarding current trading prices, IDYA is priced at $36.74, while SYRE trades at $87.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas SYRE's P/E ratio is -42.25. In terms of profitability, IDYA's ROE is -0.14%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, IDYA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check SYRE's competition here
IDYA vs LEGN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, IDYA is priced at $36.74, while LEGN trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas LEGN's P/E ratio is -42.19. In terms of profitability, IDYA's ROE is -0.14%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, IDYA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check LEGN's competition here
IDYA vs CRSP Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, IDYA is priced at $36.74, while CRSP trades at $54.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CRSP's P/E ratio is -10.75. In terms of profitability, IDYA's ROE is -0.14%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, IDYA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CRSP's competition here
IDYA vs MANE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, IDYA is priced at $36.74, while MANE trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MANE's P/E ratio is -40.29. In terms of profitability, IDYA's ROE is -0.14%, compared to MANE's ROE of -0.95%. Regarding short-term risk, IDYA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check MANE's competition here
IDYA vs APLS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IDYA is priced at $36.74, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas APLS's P/E ratio is 38.35. In terms of profitability, IDYA's ROE is -0.14%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IDYA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check APLS's competition here
IDYA vs CAI Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, IDYA is priced at $36.74, while CAI trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CAI's P/E ratio is -101.82. In terms of profitability, IDYA's ROE is -0.14%, compared to CAI's ROE of +0.06%. Regarding short-term risk, IDYA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CAI's competition here
IDYA vs ERAS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, IDYA is priced at $36.74, while ERAS trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ERAS's P/E ratio is -36.39. In terms of profitability, IDYA's ROE is -0.14%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, IDYA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ERAS's competition here
IDYA vs DFTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, IDYA is priced at $36.74, while DFTX trades at $44.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas DFTX's P/E ratio is N/A. In terms of profitability, IDYA's ROE is -0.14%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, IDYA is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DFTX's competition here
IDYA vs CELC Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CELC has a market cap of 4.9B. Regarding current trading prices, IDYA is priced at $36.74, while CELC trades at $99.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CELC's P/E ratio is -25.63. In terms of profitability, IDYA's ROE is -0.14%, compared to CELC's ROE of -2.45%. Regarding short-term risk, IDYA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CELC's competition here
IDYA vs TERN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IDYA is priced at $36.74, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas TERN's P/E ratio is -51.41. In terms of profitability, IDYA's ROE is -0.14%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IDYA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TERN's competition here
IDYA vs XENE Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, XENE has a market cap of 4.7B. Regarding current trading prices, IDYA is priced at $36.74, while XENE trades at $59.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas XENE's P/E ratio is -12.71. In terms of profitability, IDYA's ROE is -0.14%, compared to XENE's ROE of -0.49%. Regarding short-term risk, IDYA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check XENE's competition here
IDYA vs FOLD Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $36.74, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IDYA's ROE is -0.14%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IDYA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check FOLD's competition here
IDYA vs AKRO Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $36.74, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IDYA's ROE is -0.14%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, IDYA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check AKRO's competition here
IDYA vs EWTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $36.74, while EWTX trades at $41.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas EWTX's P/E ratio is -24.98. In terms of profitability, IDYA's ROE is -0.14%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, IDYA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check EWTX's competition here
IDYA vs ALPN Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IDYA is priced at $36.74, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IDYA's ROE is -0.14%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IDYA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check ALPN's competition here
IDYA vs VKTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, IDYA is priced at $36.74, while VKTX trades at $38.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas VKTX's P/E ratio is -9.19. In terms of profitability, IDYA's ROE is -0.14%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, IDYA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check VKTX's competition here
IDYA vs ACAD Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, IDYA is priced at $36.74, while ACAD trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas ACAD's P/E ratio is 12.41. In terms of profitability, IDYA's ROE is -0.14%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, IDYA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check ACAD's competition here
IDYA vs NAMSW Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, IDYA is priced at $36.74, while NAMSW trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas NAMSW's P/E ratio is -12.06. In terms of profitability, IDYA's ROE is -0.14%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, IDYA is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check NAMSW's competition here
IDYA vs OPT Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IDYA is priced at $36.74, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas OPT's P/E ratio is -1.52. In terms of profitability, IDYA's ROE is -0.14%, compared to OPT's ROE of +1.09%. Regarding short-term risk, IDYA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check OPT's competition here
IDYA vs MRTX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $36.74, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IDYA's ROE is -0.14%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IDYA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check MRTX's competition here
IDYA vs DNLI Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, IDYA is priced at $36.74, while DNLI trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas DNLI's P/E ratio is -8.88. In terms of profitability, IDYA's ROE is -0.14%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, IDYA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNLI's competition here
IDYA vs DNTH Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, IDYA is priced at $36.74, while DNTH trades at $95.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas DNTH's P/E ratio is -23.10. In terms of profitability, IDYA's ROE is -0.14%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, IDYA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check DNTH's competition here
IDYA vs TNGX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, IDYA is priced at $36.74, while TNGX trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas TNGX's P/E ratio is -37.92. In terms of profitability, IDYA's ROE is -0.14%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, IDYA is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check TNGX's competition here
IDYA vs NAMS Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, IDYA is priced at $36.74, while NAMS trades at $33.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas NAMS's P/E ratio is -20.91. In terms of profitability, IDYA's ROE is -0.14%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, IDYA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check NAMS's competition here
IDYA vs CRNX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, IDYA is priced at $36.74, while CRNX trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CRNX's P/E ratio is -7.15. In terms of profitability, IDYA's ROE is -0.14%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IDYA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check CRNX's competition here
IDYA vs CPRX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, IDYA is priced at $36.74, while CPRX trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CPRX's P/E ratio is 11.33. In terms of profitability, IDYA's ROE is -0.14%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, IDYA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CPRX's competition here
IDYA vs RYZB Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IDYA is priced at $36.74, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IDYA's ROE is -0.14%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IDYA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check RYZB's competition here
IDYA vs CBAY Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IDYA is priced at $36.74, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IDYA's ROE is -0.14%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IDYA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check CBAY's competition here
IDYA vs TLX Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, IDYA is priced at $36.74, while TLX trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas TLX's P/E ratio is -580.29. In terms of profitability, IDYA's ROE is -0.14%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IDYA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IDYA.Check TLX's competition here
IDYA vs BEAM Comparison July 2026
IDYA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IDYA stands at 3.5B. In comparison, BEAM has a market cap of 3.6B. Regarding current trading prices, IDYA is priced at $36.74, while BEAM trades at $34.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IDYA currently has a P/E ratio of -22.96, whereas BEAM's P/E ratio is -11.19. In terms of profitability, IDYA's ROE is -0.14%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, IDYA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for IDYA.Check BEAM's competition here